Related Experiment Video
Updated: Jan 31, 2026

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
Published on: September 3, 2016
SUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity
Mohammed A M Salih1,2,3, Mohamed M A E L Salem4, Muhammad Ali Shahid1
1Institute of Cancer Therapeutics, University of Bradford, Bradford, UK.
Purpose:
Breast cancer is a significant global health issue, with resistance to doxorubicin (DOX) posing a major challenge to effective treatment. SUMOylation, a post-translational modification process, is linked to cancer progression and therapy resistance. PIAS4, a SUMO E3 ligase involved in maintaining genome stability and stress response, may play a role in these mechanisms. However, its function in breast cancer progression and DOX resistance remains uncertain. This study investigates the potential role of PIAS4 in mediating DOX resistance in breast cancer.
Methods And Results:
Naked mole-rats (NMRs) are cancer-resistant rodents with improved genome maintenance, yet the role of SUMOylation in this trait remains unclear. SUMOylation machinery gene expression levels are investigated using qPCR in NMR tissue in comparison with carcinogenic breast cancer (MCF-7) cell line. Functional studies are performed in MCF-7 cells overexpressing PIAS4 to demonstrate effects on proliferation, invasion, drug sensitivity, and protein expression in the presence and absence of DOX treatment. While most SUMOylation genes were expressed at low levels in NMR intestinal tissues, PIAS4 showed higher expression compared to MCF-7 cells. PIAS4 overexpression in MCF-7 cells significantly decreases colony formation, invasiveness, and resistance to DOX. Western blot analysis showed downregulated Bcl-2 protein levels after DOX treatment, indicating a potential role in apoptosis evasion.
Conclusion:
PIAS4 expression level plays a role in breast cancer cell survival, invasiveness, and chemoresistance, partly by altering anti-apoptotic pathways. These findings position PIAS4 as a potential biomarker and therapeutic target for overcoming resistance to anthracycline-based therapies in breast cancer.
Insights
PIAS4 protein may overcome doxorubicin resistance in breast cancer by reducing cell survival and invasiveness. This finding suggests PIAS4 as a potential therapeutic target for improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer presents a significant global health challenge, with doxorubicin (DOX) resistance impeding effective treatment.
- SUMOylation, a post-translational modification, is implicated in cancer progression and therapy resistance.
- PIAS4, a SUMO E3 ligase, is involved in genome stability and stress response, but its role in breast cancer and DOX resistance is unclear.
Purpose of the Study:
- To investigate the role of PIAS4 in mediating doxorubicin resistance in breast cancer.
- To explore PIAS4's function in breast cancer progression and its impact on chemoresistance.
Main Methods:
- Quantitative PCR (qPCR) to compare SUMOylation gene expression in naked mole-rats (NMRs) and breast cancer cells (MCF-7).
- Functional studies in MCF-7 cells overexpressing PIAS4 to assess proliferation, invasion, and drug sensitivity.
- Western blot analysis to examine protein expression changes, including Bcl-2, after doxorubicin treatment.
Main Results:
- PIAS4 exhibited higher expression in NMR intestinal tissue compared to MCF-7 cells.
- Overexpression of PIAS4 in MCF-7 cells significantly reduced colony formation, invasiveness, and doxorubicin resistance.
- Doxorubicin treatment led to downregulated Bcl-2 protein levels in PIAS4-overexpressing cells, suggesting a role in apoptosis.
Conclusions:
- PIAS4 expression influences breast cancer cell survival, invasiveness, and chemoresistance, partly through modulation of anti-apoptotic pathways.
- PIAS4 emerges as a potential biomarker for predicting treatment response.
- Targeting PIAS4 could be a therapeutic strategy to overcome anthracycline resistance in breast cancer.
Related Concept Videos
Protein Translocation Machinery on the ER Membrane
Sec61 protein conducting channel
In eukaryotes, the translocon complex comprises a core heterotrimeric translocator channel called the Sec61 complex. This channel includes three transmembrane proteins, Sec61α, Sec61β, and Sec61γ, and is the largest subunit of the...
Role of Proteins in the Human Body
Hepatic Drug Clearance: Role of Transporters
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...

